Cagrilintide Powder (CAS 1415456-99-3)

As a premier Cagrilintide manufacture and global supplier, SuperPharmaGroup specializes in complex acylated peptide synthesis for metabolic disease research. Cagrilintide (chemically designated as CAS 1415456-99-3) represents a novel, non-selective, long-acting amylin receptor agonist (AMYR) and calcitonin receptor agonist (CTR). SuperPharmaGroup utilizes solid-phase peptide synthesis (SPPS) and specialized acylation technology to deliver ultra-pure Cagrilintide.

Core Innovation & Advantages

• Q: What provides the prolonged half-life of Cagrilintide?

  • A: The C20 eicosanedioic acid-γ-Glu fatty diacid chain promotes strong, reversible non-covalent binding to circulating plasma albumin. This design creates a continuous depot effect, extending half-life to approximately 7 days for weekly administration protocols.

• Q: What unique properties distinguish SuperPharmaGroup's synthesis?

  • A: Precise intramolecular disulfide bond closure (Cys2-Cys7) prevents self-aggregation and fibril formation. Advanced RP-HPLC purification eliminates acylation isomers and truncated peptide impurities.

Compliance & Express Logistics

Partnering with an established Cagrilintide manufacture ensures complete analytical batch traceability and export compliance. SuperPharmaGroup provides a comprehensive regulatory package for every CAS 1415456-99-3 order:

• Certificate of Analysis (COA) & High-Performance Liquid Chromatography (HPLC) Profile

• Mass Spectrometry (MS) Identity Confirmation & Safety Data Sheet (SDS)

• cGMP & ISO 9001 Compliant Peptide Production Facilities

• Temperature-Controlled Cold-Chain (Dry Ice / Sealed Gel Ice) Express Delivery

Contact this Cagrilintide supplier team to access factory-direct pricing, custom lyophilized vial filling (e.g., 2mg, 5mg, 10mg), and rapid international shipping.